SC 13G: iBio, Inc.
Ticker: IBIO · Form: SC 13G · Filed: 2024-11-14T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by iBio, Inc..
Risk Assessment
Risk Level: low
From the Filing
0001193125-24-259076.txt : 20241114 0001193125-24-259076.hdr.sgml : 20241114 20241114204749 ACCESSION NUMBER: 0001193125-24-259076 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20241114 DATE AS OF CHANGE: 20241114 GROUP MEMBERS: NEIL SHAHRESTANI SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-84151 FILM NUMBER: 241465508 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ikarian Capital, LLC CENTRAL INDEX KEY: 0001778253 ORGANIZATION NAME: IRS NUMBER: 473466768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 100 CRESCENT COURT STREET 2: SUITE 1620 CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: 214-364-2883 MAIL ADDRESS: STREET 1: 100 CRESCENT COURT STREET 2: SUITE 1620 CITY: DALLAS STATE: TX ZIP: 75201 SC 13G 1 d893918dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IBIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 451033708 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications: Evan K. Hall, Esq. Haynes and Boone, LLP 2801 N. Harwood Street, Suite 2300 Dallas, Texas 75201 (214) 651-5000 SCHEDULE 13G CUSIP No. 451033708  1   Names of Reporting Persons  Ikarian Capital, LLC  2  Check the appropriate box if a member of a Group (see instructions)  (a) ☐  (b) ☒  3  Sec Use Only  4  Citizenship or Place of Organization  Delaware Number of Shares Beneficially  Owned by Each Reporting Person With: 5   Sole Voting Power  0 6  Shared Voting Power  599,913 (1) 7  Sole Dispositive Power  0 8  Shared Dispositive Power  599,913 (1)  9   Aggregate Amount Beneficially Owned by Each Reporting Person  599,913 (1) 10  Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  ☐ 11  Percent of class represented by amount in row (9)  6.6% (1)(2) 12  Type of Reporting Person (See Instructions)  IA (1) Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. Se